VSNOVA platform thesis
Build one measurement core.Earn every application.
VSNOVA brings controlled breath capture, multi-signal sensing, calibration and source-aware modelling into one developing platform. Devices share the engineering core, never the evidence claim.
Current buildVAYU instrument + clinic-connected respiratory programme
Core technical uncertainty
Can a breath signal remain comparable across people, time and sites?
The central R&D problem is not detecting a changing sensor response. It is determining whether controlled capture, calibration and source correction can produce a repeatable signal that remains linked to one predefined biological endpoint across days, instruments, operators and populations.
Controlled sampling
Breath fraction, flow, humidity, cartridge and collection quality.
The moat is the complete chain, not one sensor or one model.
The platform architecture
Hardware, care context and data advance together.
VAYU is the physical measurement engine. The digital programme is the clinical operating layer. Paired data is designed to become the accumulating advantage.
- 01
VAYU measurement engine
Controlled capture, multi-signal sensing, calibration and source-aware modelling.
- 02
Clinical operating layer
Partner-clinic context and digital follow-through around chronic respiratory health.
- 03
Paired data asset
A planned corpus linking breath, environment, longitudinal context and reference measures.
- 04
Application products
Separate models and intended uses for respiratory, oncology, gut-brain and respiratory-infection research pathways.
The paired dataset is a planned asset under development. It is not presented as an existing validated proprietary corpus.
Protectable system
The moat is the chain, not a single sensor.
The defensible surface is intended to span physical design, calibration, technically implemented correction and application-specific models. Patentability and ownership remain subject to formal review and filing.
- 01
Sampling system
Breath fraction control, flow and humidity measurement, cartridge design and sample-quality gating.
- 02
Sensing + calibration
Multi-channel response, interferent handling, blanks, drift correction and instrument quality control.
- 03
Technical source correction
Methods that account for ambient, oral, airway, systemic and instrument contributions.
- 04
Disease-specific models
Locked computational endpoints connected to explicit reference methods and independent evaluation.
What the next build unlocks
Capital becomes measurable platform assets.
The next development phase concentrates effort in the physical instrument, analytical controls, paired studies and partner-site operation needed to reduce technical risk.
- 01Integrated VAYU instrument iterations
- 02Calibration and interferent studies
- 03Paired breath and reference cohorts
- 04Quality-locked source-correction models
- 05Partner-site research deployments
Commercial platform engine
The programme, instrument and paired data are designed to strengthen one another.
Clinic-connected programme
An operating layer designed for partner clinics around COPD and chronic respiratory support.
DPIIT assessment context
The case is the work, not the label.
VSNOVA is preparing an application around an integrated biological-measurement platform, not a software wrapper or an off-the-shelf sensor. The case depends on company-specific R&D records, measured technical risk reduction, IP review and a credible path from research instrumentation to separately validated applications. Recognition remains subject to DPIIT assessment.
Read the official notification- 01Integrated advancement
Controlled sampling, multi-signal sensing, calibration and source-aware modelling operate as one quality-gated system.
- 02R&D programme
Instrument iterations, interferent studies, repeatability tests and paired breath-reference cohorts.
- 03Technical uncertainty
Repeatability, source attribution, biological linkage and site transfer remain open measurement questions.
- 04Potential IP
Sampling, calibration, correction and locked application models are under novelty and ownership review.
- 05Commercial pathway
The clinic-connected programme and developing instrument form the initial route; later products remain validation-dependent.
Oncology horizon
A cancer signal must survive the real world.
Breath-oncology studies are promising, but smoking, diet, comorbidities and other diseases can reshape VOC patterns. The VSNOVA thesis is to build source correction, longitudinal context and reference linkage into the platform before asking a disease-specific question.
Examine the confounding evidenceFuture research only. VSNOVA has no current cancer screening, diagnosis, monitoring or treatment capability.
A future screening-support question, tested only against established reference diagnostics in an appropriate cohort.
Long-horizon research
From individual phenotypes to respiratory preparedness.
Infection can change host metabolism, airway inflammation and microbial activity. The platform horizon is to study these layers. A VOC pattern alone would not identify a virus, bacterium, strain or source.
- 01
Host-response phenotype
Investigate candidate VOC patterns associated with airway inflammation, oxidative stress and microbial metabolism.
- 02
Exhaled-particle capture
A separate future sampling pathway linked to target-specific molecular or microbiological assays.
- 03
Aggregate anomaly research
Study privacy-preserving approaches to aggregate departures from a defined baseline under clinical and public-health governance.
Research horizon only. VOC phenotyping alone cannot identify a pathogen, confirm an outbreak or attribute a biosecurity event. Those uses require purpose-built assays, confirmatory laboratories and independent public-health validation.
See how the architecture becomes a product system.
VAYU is the active physical build. Controlled sampling and context sensing show how the same measurement obligations can extend into a staged product family.